Citrafleet (Sodium Picosulfate, Magnesium Oxide, Light, Citric Acid)

The product is typically mixed with a specified volume of water and consumed in divided doses according to the prescribing information, followed by additional clear fluids to maintain hydration. Exact timing should be confirmed with the healthcare provider.

Renal function should be evaluated before use because magnesium oxide can affect electrolyte balance. Patients with severe renal impairment may require an alternative bowel‑cleansing regimen.

Common side effects include abdominal cramping, diarrhea, nausea, thirst, bloating, and mild, transient changes in electrolyte levels such as low potassium.

Citrafleet should be avoided in individuals with known or suspected bowel obstruction, perforation, or severe inflammatory bowel disease, and in patients with hypersensitivity to any of its components.

Safety in pregnancy has not been established. Healthcare providers usually consider alternative bowel‑cleansing agents for pregnant patients unless the benefits outweigh potential risks.

Patients are generally advised to drink plenty of clear fluids (often at least 2‑3 L) during the preparation period to reduce the risk of dehydration and electrolyte disturbances.

Concurrent use of other potent laxatives or stool softeners is generally avoided to prevent excessive fluid loss and severe electrolyte imbalance.

Seek medical attention promptly. Severe dehydration may require intravenous fluid replacement and monitoring of electrolyte levels.

Citrafleet can affect potassium levels; therefore, caution is advised when used with ACE inhibitors, ARBs, or potassium‑sparing diuretics, as the combination may increase the risk of hyper‑ or hypokalemia.

A repeat dose should only be administered under medical supervision. Unsupervised additional dosing can increase the risk of adverse events.

The cleansing effect typically occurs within 4‑6 hours after the final dose, providing a clear colon suitable for endoscopic or radiologic evaluation.